Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan in Advanced Thymic Carcinoma
NCT07324629Phase 2Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Mar 2026
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in thymic carcinoma (TC), sponsored by Kelun-Biotech. Started Mar 2026; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on NCT07324629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07324629.